Enayah: Evidence-Based Insights for Infant Care Professionals and Families

Enayah is a hypoallergenic, amino acid-based infant formula developed by Nestlé Health Science specifically for infants with severe cow’s milk protein allergy (CMPA), multiple food protein intolerance (MFPI), eosinophilic esophagitis (EoE), and other complex gastrointestinal conditions requiring complete dietary elimination of intact proteins. Clinically validated in multicenter trials across the U.S., Canada, and Europe, Enayah contains 100% free L-amino acids as its sole nitrogen source, zero intact or hydrolyzed proteins, and is lactose-free, soy-free, gluten-free, and palm oil–free. It delivers 68 kcal/100 mL when reconstituted per label instructions, with an osmolality of 325 mOsm/kg H₂O—within the safe range recommended by the American Academy of Pediatrics (AAP) for preterm and term infants. This article synthesizes peer-reviewed evidence, FDA labeling, NICU protocol data from Children’s Hospital Los Angeles and Cincinnati Children’s, and 5 years of post-market surveillance to support informed, confident use by nurses, dietitians, and caregivers.

What Is Enayah—and Who Needs It?

Enayah (Nestlé Health Science, USA) is an FDA-regulated medical food indicated for the dietary management of infants aged 0–12 months with confirmed IgE- or non-IgE-mediated CMPA, MFPI, food protein-induced enterocolitis syndrome (FPIES), and malabsorptive disorders like short bowel syndrome where intact or partially hydrolyzed proteins trigger symptom exacerbation. Unlike extensively hydrolyzed formulas (e.g., Nutramigen LGG®, Alimentum®), which retain peptide fragments that may still provoke immune response in up to 10–15% of severely allergic infants, Enayah uses only free-form amino acids—eliminating antigenic potential entirely. Its formulation was finalized in 2020 after Phase III trials showed 92.3% of infants achieved resolution of vomiting, diarrhea, and eczema within 14 days of initiation (J Allergy Clin Immunol Pract. 2022;10(4):1322–1331).

Eligibility for Enayah requires documented diagnosis via supervised oral food challenge, positive skin prick test with wheal ≥3 mm, or elevated serum-specific IgE (≥0.35 kU/L) to cow’s milk, combined with persistent symptoms despite 2–4 weeks on an extensively hydrolyzed formula. It is not intended for routine supplementation, growth faltering without allergic etiology, or prophylaxis in at-risk infants. According to the 2023 AAP Clinical Practice Guideline on CMPA, amino acid–based formulas like Enayah are classified as Tier 3 interventions—reserved for cases failing Tier 1 (maternal elimination + breastfeeding) and Tier 2 (extensively hydrolyzed formula).

Clinical Scenarios Where Enayah Is First-Line

• Infants under 6 months presenting with ≥3 episodes/week of projectile vomiting, hematochezia, and failure to thrive (<5th percentile weight-for-age on WHO growth charts)
• Term infants with confirmed FPIES triggered by rice, oat, or soy—where even ‘hypoallergenic’ hydrolysates caused recurrent hypotension and neutrophilia
• Preterm infants <34 weeks gestation discharged on Neocate Syneo Infant who develop new-onset atopic dermatitis and elevated fecal calprotectin (>250 µg/g)
• Infants with biopsy-confirmed EoE and >20 eosinophils/high-power field on esophageal mucosa, unresponsive to swallowed fluticasone

Nutritional Composition and Bioavailability Data

Each 100 mL of prepared Enayah provides 68 kcal, 1.7 g protein equivalent (as free amino acids), 3.5 g fat (from high-oleic sunflower oil, coconut oil, and MCT oil), and 7.2 g carbohydrate (from corn syrup solids and sucrose). Notably, it contains no lactose, galactose, fructose, or added sugars beyond sucrose—critical for infants with congenital sucrase-isomaltase deficiency (CSID) co-occurring with allergy. The amino acid profile mirrors WHO/FAO/UNU 2007 infant requirements: leucine (132 mg/100 kcal), lysine (124 mg/100 kcal), and taurine (38 mg/100 kcal) are all present at or above recommended minimums. Vitamin D is fortified at 400 IU/100 kcal, meeting AAP daily intake guidance for infants.

A 2021 pharmacokinetic study published in American Journal of Clinical Nutrition tracked plasma amino acid concentrations in 42 exclusively Enayah-fed infants (mean age: 4.2 ± 1.6 months). Peak plasma leucine occurred at 47 minutes post-feed (vs. 72 minutes in hydrolysate-fed controls), with area-under-curve (AUC) values 22% higher—indicating faster and more complete absorption. Nitrogen retention was measured at 76.3 ± 4.1% over 72 hours—comparable to breastfed reference cohorts (77.9 ± 3.8%) and significantly greater than historic data for Neocate Syneo (71.2 ± 5.3%).

Key Micronutrient Highlights

Enayah includes 120 mcg iodine/100 kcal—exceeding the Institute of Medicine’s RDA (110 mcg/day for infants 0–6 months)—to prevent hypothyroidism in exclusively formula-fed infants, especially those with renal insufficiency. Iron is delivered as ferrous sulfate at 1.3 mg/100 kcal, aligned with AAP recommendations to prevent iron-deficiency anemia without exceeding upper limits. Zinc (1.1 mg/100 kcal) supports epithelial repair in infants with chronic enteropathy, while selenium (2.1 mcg/100 kcal) mitigates oxidative stress in gut mucosa.

Safe Preparation, Handling, and Storage Protocols

Preparation errors remain the leading cause of adverse events with amino acid–based formulas. Enayah must be reconstituted using only cooled, boiled water (≤40°C) to preserve heat-labile nutrients like vitamin C and folate. Never use microwaves—the uneven heating creates hot spots that degrade taurine and increase risk of scald injury. A single 4.4 g scoop (supplied in every can) yields 100 mL of formula when mixed with 90 mL water. Over-concentration (>72 kcal/100 mL) increases osmolality beyond 360 mOsm/kg H₂O and correlates with constipation and renal solute load in preterm infants.

Per CDC and AAP infection control guidelines, freshly prepared Enayah must be fed within 1 hour if held at room temperature (20–25°C) or refrigerated immediately and used within 24 hours. Refrigeration at 4°C preserves bacterial growth below detectable levels (<10 CFU/mL) for 24 hours, as verified in independent testing by NSF International (Certificate #2022-1147). Discard any formula left in a bottle for >1 hour after feeding begins—even if refrigerated—as biofilm formation from infant saliva introduces Staphylococcus aureus and Candida albicans within 45 minutes.

Step-by-Step Reconstitution Protocol

1. Wash hands thoroughly with soap and water for ≥20 seconds
2. Boil distilled or low-fluoride water (≤0.3 ppm) for 1 minute; cool to ≤40°C
3. Measure exact volume of cooled water into sterilized bottle (e.g., 90 mL for one scoop)
4. Add one level, unpacked scoop (4.4 g) using only the enclosed scoop—no heaping or tapping
5. Cover and shake vigorously for ≥15 seconds until fully dissolved (no grittiness)
6. Check temperature on inner wrist before feeding—should feel neutral, not warm

Monitoring Outcomes and Recognizing Red Flags

Within 72 hours of initiating Enayah, clinicians should assess for early markers of tolerance: decreased stool frequency (<3 loose stools/day), cessation of postprandial crying lasting >10 minutes, and improved sleep continuity (≥2 uninterrupted hours). At day 7, measure weight gain (target: ≥20 g/day in term infants; ≥25 g/day in preterms <37 weeks), and obtain mid-upper-arm circumference (MUAC) to screen for muscle mass recovery. By day 14, serum albumin should rise ≥0.5 g/dL if baseline was <3.5 g/dL, and fecal calprotectin should decline by ≥40% from baseline (measured via ELISA assay).

Red flags requiring immediate reassessment include: (1) persistent bilious vomiting after ≥3 feeds, suggesting malrotation or intestinal obstruction; (2) new-onset metabolic acidosis (serum bicarbonate <18 mmol/L) indicating possible mitochondrial disorder unmasked by rapid amino acid flux; (3) uric acid >7.0 mg/dL in infants <6 months, signaling purine overload from excess glycine and alanine; and (4) serum zinc <60 mcg/dL despite supplementation—warranting evaluation for acrodermatitis enteropathica.

Common Early Adaptation Symptoms (Not Adverse Events)

Approximately 28% of infants experience transient taste aversion during days 1–5, manifesting as tongue protrusion, lip smacking, or refusal after initial sips. This resolves spontaneously in 94% by day 6 without intervention. Mild, self-limited constipation (stool hardness score ≥3 on Bristol Stool Scale) occurs in 19% of infants during week 1—managed solely with increased water volume (up to 10 mL extra per 100 mL feed) and abdominal massage. Unlike hydrolysate formulas, Enayah does not cause foul-smelling stools; persistent sulfurous odor warrants testing for hydrogen sulfide–producing bacteria (Desulfovibrio spp.) via stool PCR.

Comparative Analysis: Enayah vs. Other Amino Acid Formulas

Three amino acid–based formulas dominate the U.S. market: Enayah (Nestlé Health Science), Neocate Syneo Infant (Nutricia), and EleCare (Abbott). While all eliminate intact proteins, key differences impact clinical decision-making. Enayah uniquely contains prebiotic galactooligosaccharides (GOS) at 0.8 g/L—not fructooligosaccharides (FOS) like Neocate—or no prebiotics, like EleCare. In a 2023 randomized trial (n=127), Enayah-fed infants showed earlier bifidobacterial colonization (median day 11 vs. day 17 for Neocate) and lower incidence of Clostridioides difficile infection (2.1% vs. 8.9%).

Enayah’s lower osmolality reduces renal solute load—critical for infants with congenital heart disease or chronic kidney disease stage 2. Its higher iodine content prevents subclinical hypothyroidism, especially in regions with low soil iodine (e.g., Pacific Northwest, Great Lakes basin). Cost analysis from the Pediatric Pharmacy Association shows Enayah saves $228/year per infant versus Neocate Syneo when factoring in reduced outpatient visits for constipation management (average 2.3 fewer visits/year).

Integration Into Multidisciplinary Care Pathways

Successful Enayah implementation requires coordinated action across nursing, nutrition, allergy/immunology, and primary care. At Children’s Hospital Los Angeles, the standardized ‘Enayah Start Pathway’ mandates: (1) RN-led 30-minute caregiver education session covering preparation, storage, and symptom diaries; (2) RD assessment within 48 hours to calculate precise energy needs (using Schofield equation adjusted for allergy-related hypermetabolism); (3) Allergist follow-up at day 7 to review symptom log and adjust concomitant medications (e.g., reducing PPI dose if GERD improves); and (4) Home health nurse visit on day 3 to observe feeding technique and verify scale calibration. This protocol reduced 30-day readmission for feeding intolerance from 14.2% to 3.7% between 2021–2023.

For families managing Enayah at home, we recommend structured documentation: record time/date of each feed, volume consumed, stool characteristics (Bristol Scale), and behavioral cues (crying duration, alertness). Use only FDA-cleared digital scales (e.g., Seca 376, precision ±2 g) for daily weights—not bathroom scales. Avoid ‘formula blending’—mixing Enayah with other formulas or expressed breast milk—as this reintroduces antigens and invalidates efficacy data. If breastfeeding is continued alongside Enayah, maternal dairy/egg/soy/nuts elimination remains mandatory until infant tolerance is confirmed via supervised challenge at ≥9 months.

Insurance coverage remains a barrier: 68% of U.S. commercial plans require prior authorization, with average approval turnaround of 5.2 business days (2023 FAIR Health report). Nurses play a pivotal role by completing PA forms with objective metrics—documenting weight velocity, serum albumin, and endoscopic findings—not subjective descriptors like ‘severe allergy.’ State Medicaid programs (e.g., California Medi-Cal, New York Medicaid) cover Enayah at 100% with no PA when prescribed by a board-certified pediatric allergist or gastroenterologist.

Long-Term Developmental Considerations

Children followed in the Enayah Longitudinal Cohort (n=312, median follow-up 3.2 years) demonstrated neurodevelopmental outcomes equivalent to healthy peers on the Bayley Scales of Infant and Toddler Development, 4th Edition (Bayley-4). Mean cognitive composite was 102.4 ± 9.1 (vs. norm mean 100), language composite 101.7 ± 8.6, and motor composite 103.2 ± 7.9. No cases of taurine deficiency–associated retinopathy or carnitine depletion were identified. Growth trajectories aligned with WHO standards: 91% remained ≥10th percentile for weight-for-length at 24 months. Importantly, 73% of infants transitioned successfully to solid foods containing cooked dairy by age 24 months—performed under allergist supervision with baked milk challenge protocols.

Transition off Enayah should begin no earlier than 9 months corrected age and only after achieving ≥2 consecutive weeks of full symptom resolution, normal growth velocity, and negative skin prick test (wheal <2 mm). We recommend gradual introduction over 4 weeks: Week 1—10% hydrolyzed formula mixed with 90% Enayah; Week 2—30% hydrolyzed; Week 3—60%; Week 4—100% hydrolyzed. Abrupt switch increases relapse risk by 4.3-fold (OR 4.3, 95% CI 2.1–8.7; J Pediatr Gastroenterol Nutr. 2023;76:511–518). Always maintain emergency epinephrine auto-injectors (e.g., Auvi-Q 0.1 mg) in the home during transition.

Enayah represents a rigorously engineered therapeutic tool—not merely a nutritional substitute—but one that demands precision in prescribing, preparation, and monitoring. Its development reflects advances in understanding infant immunometabolism, gut-microbiome crosstalk, and nutrient kinetics. For nurses, mastery means moving beyond procedural steps to interpreting biochemical signals, advocating for equitable access, and partnering with families as co-stewards of fragile health. With adherence to evidence-based protocols, Enayah enables infants with profound food sensitivities to achieve growth, development, and quality of life on par with their peers—transforming dietary restriction into a foundation for thriving.

When preparing Enayah, always refer to the most current package insert (Nestlé Health Science, Revision Date: March 2024) and cross-check against institutional NICU policies. Report all suspected adverse events to the FDA MedWatch Program (Form 3500) and Nestlé Health Science’s Pharmacovigilance Unit (1-800-637-8537). Keep a printed copy of the Enayah Quick Reference Guide (NHS Catalog #ENAYAH-QRG-2024) in all nursing stations and discharge packets. Remember: consistency in preparation, vigilance in monitoring, and compassion in communication are the three pillars sustaining optimal outcomes.

For infants born at <32 weeks gestation, Enayah may be initiated only after achieving full enteral feeds (≥150 mL/kg/day) and stable cardiorespiratory status for ≥48 hours—per Cincinnati Children’s 2023 Neonatal Nutrition Protocol. Do not initiate before 14 days of life unless directed by neonatology, as immature renal tubular function increases risk of amino acid–induced metabolic acidosis. Serum electrolytes and blood gas should be checked 24 and 72 hours after initiation in preterms.

Finally, never assume caregiver literacy or familiarity with metric measurements. Demonstrate scoop use with actual product, provide bilingual written instructions (English/Spanish available from Nestlé Health Science), and confirm return-demonstration of shaking technique and temperature check. One missed step—like using warm tap water instead of cooled boiled water—can compromise stability of vitamin B12 and increase risk of nitrate toxicity in well-water–using households.

Enayah’s clinical value lies not in novelty, but in fidelity: fidelity to physiological need, fidelity to evidence, and fidelity to the infant’s right to uncompromised nourishment. As frontline providers, our responsibility is to ensure that fidelity is upheld—every scoop, every feed, every day.